WELCOME TO The PHARMACEUTICAL REPORT
Newsletter | Member Login | Signup
Home > Companies > Pharmaceutical Manufacturing Technology Centre
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
PHARMACY MARKET
Ionis Pharmaceuticals, Inc. | December 30, 2021
Ionis Pharmaceuticals, Inc. the leader in RNA-targeted therapies, announced the closing of the collaboration agreement with AstraZeneca to develop and commercialize eplontersen, Ionis' investigational antisense medicine for the treatment of transthyretin amyloidosis, following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Eplontersen, formerly known as IONIS-TTR-LRx, is designed to reduce the production of transthy...
RESEARCH
Moderna | June 08, 2021
Moderna, Inc., a biotechnology company that pioneered messenger RNA (mRNA) therapeutics and vaccines, and Medison Pharma, a leading commercial partner for highly innovative therapies in international markets, announced today a new agreement to commercialize the Moderna COVID-19 Vaccine in Central Eastern Europe and Israel. Poland, Czech Republic, Romania, Hungary, Bulgaria, Slovenia, Slovakia, Croatia, Estonia, Latvia, Lithuania, Serbia, Ukraine, Moldova, Albania, Bosnia, and Herz...
BUSINESS INSIGHTS
PhaseBio Pharmaceuticals, Inc. | February 25, 2022
PhaseBio Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that Chief Executive Officer Jonathan P. Mow will participate in a panel discussion during Cowen’s 42nd Annual Health Care Conference taking place virtually on Tuesday, March 8, 2022 from 12:50 pm – 1:50 pm ET. Interested parties can access the live and archived webcasts of the virtual...
Debiopharm International SA | January 11, 2022
Debiopharm a Swiss biopharmaceutical company, announced their co-investment in California-based start-up VeriSIM Life's $15 Million Series A Round to advance their mission to accelerate drug development via technology powered by artificial intelligence. VeriSIM Life's computational platform reduces time and cost of drug development as well as reduces the need for animal testing that, in the vast majority of cases, does not translate well to humans. Debiopharm's co-investment in VeriS...
Article
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE